Non-Carriers of Reduced-Function CYP2C19 Alleles are Most Susceptible to Impairment of the Anti-Platelet Effect of Clopidogrel by Proton-Pump Inhibitors: A Pilot Study.

MLA

Lee, Jen-Kuang, et al. “Non-Carriers of Reduced-Function CYP2C19 Alleles Are Most Susceptible to Impairment of the Anti-Platelet Effect of Clopidogrel by Proton-Pump Inhibitors: A Pilot Study.” Acta Cardiologica Sinica, vol. 32, no. 2, Mar. 2016, pp. 215–22. EBSCOhost, https://doi.org/10.6515/acs20160201a.

APA

Lee, J.-K., Wu, C.-K., Juang, J.-M., Tsai, C.-T., Hwang, J.-J., Lin, J.-L., & Chiang, F.-T. (2016). Non-Carriers of Reduced-Function CYP2C19 Alleles are Most Susceptible to Impairment of the Anti-Platelet Effect of Clopidogrel by Proton-Pump Inhibitors: A Pilot Study. Acta Cardiologica Sinica, 32(2), 215–222. https://doi.org/10.6515/acs20160201a

Chicago

Lee, Jen-Kuang, Cho-Kai Wu, Jyh-Ming Juang, Chia-Ti Tsai, Juey-Jen Hwang, Jiuun-Lee Lin, and Fu-Tien Chiang. 2016. “Non-Carriers of Reduced-Function CYP2C19 Alleles Are Most Susceptible to Impairment of the Anti-Platelet Effect of Clopidogrel by Proton-Pump Inhibitors: A Pilot Study.” Acta Cardiologica Sinica 32 (2): 215–22. doi:10.6515/acs20160201a.